Trk receptor
Trk receptor inhibitors target the Tropomyosin receptor kinases (Trk), a family of receptor tyrosine kinases that play a significant role in the development and function of the nervous system. Trk receptors are involved in neurotrophin signaling, which is essential for the survival, differentiation, and growth of neurons. Dysregulation of Trk signaling is associated with neurological disorders and certain cancers. At CymitQuimica, we offer Trk receptor inhibitors to support your research in neurobiology, oncology, and neurodegenerative diseases.
Found 56 products of "Trk receptor"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Paltimatrectinib
CAS:Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.Formula:C20H15F5N6Purity:99.96%Color and Shape:SolidMolecular weight:434.37TRK-IN-24
CAS:TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,Formula:C39H45N7O3Purity:98%Color and Shape:SolidMolecular weight:659.82Type II TRK inhibitor 1
CAS:Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.Formula:C35H33F3N8O3Purity:98%Color and Shape:SolidMolecular weight:670.68AZ-23
CAS:AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.Formula:C17H19ClFN7OPurity:99.4%Color and Shape:SolidMolecular weight:391.83TrkA-IN-9
CAS:TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61TrkC-IN-1
CAS:TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Formula:C28H20BrN5O2Color and Shape:SolidMolecular weight:538.395BNN-20
CAS:BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.Formula:C20H30O2Color and Shape:SolidMolecular weight:302.45TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Formula:C27H25F2N7Color and Shape:SolidMolecular weight:485.53TRK-IN-26
CAS:TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].Formula:C30H22F2N6O4Color and Shape:SolidMolecular weight:568.53TrkA-IN-7
CAS:TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.Formula:C16H13N3O3Color and Shape:SolidMolecular weight:295.293PF-06273340
CAS:PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。Formula:C23H22ClN7O3Purity:98% - 98.00%Color and Shape:SolidMolecular weight:479.92TrkA-IN-8
CAS:TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368NMS-P626
CAS:NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.Formula:C28H35F2N7O4SColor and Shape:SolidMolecular weight:603.68ONO-7579
CAS:ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.Formula:C24H18ClF3N6O4SColor and Shape:SolidMolecular weight:578.95Trk-IN-4
CAS:Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.Formula:C24H23F4N5O4Purity:98.13%Color and Shape:SolidMolecular weight:521.46TrkB-IN-1
CAS:TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.
Formula:C19H16N2O6Purity:98%Color and Shape:SolidMolecular weight:368.34
